Lotion Manufacturing Company Business Plan by fbx82765

VIEWS: 0 PAGES: 12

More Info
									Mid-Term Business Plan
“Sunrise 2010”
Challenge of “New 2010 Targets”



                CHUGAI PHARMACEUTICAL CO., LTD.
                President and CEO
                Osamu Nagayama

                February 9/10, 2006
Forward Looking Statements

 This presentation may include forward looking
statements pertaining to the business and prospects
of Chugai Pharmaceutical Co., Ltd. (the “Company”)
These statements reflect the Company’s current
analysis of existing information and trends. Actual
results may differ from expectations based on risks
and uncertainties that may affect the Company’s
businesses.
Mid-Term Business Plan ”Sunrise 2010”

Planning period: FY 2005-FY 2010
    2002 – 2004: Integration = Maximization of integration synergies
    2005 – 2010: Transformation = Realization of “Transformation”
      • Aim for quantum leaps towards being a top-class
        pharmaceutical company

               Sales
             synergies




 R&D                     Cost
 synergies               synergies
Challenge of “New 2010 Targets”

  FY 2010 targets     New FY 2010 targets

Consolidated sales     Consolidated sales

> JPY 360.0 billion       JPY 450.0 billion

Consolidated           Consolidated
operating profit       operating profit
             > 20 %       JPY 100.0 billion
Background of the New 2010 Targets
Excellent progress in the development of major projects
   ACTEMRA
    • RA: Promising results in Japanese PIII study, favorable progress in
           overseas PIII study in collaboration with Roche
   AVASTIN
    • CRC: Requests for earlier filing from “Investigational committee for
           usage of unapproved drugs”
    • NSCLC, BC: Promising results in overseas PIII study
   HERCEPTIN
    • BC (Adjuvant): Promising results in multinational PIII study
Strengthening of competitiveness
   Establishment of strategic marketing functions and specialized MRs, reform
   of manufacturing system, etc
Perspective on severe price cuts (April, 2006)
  Steps toward New FY 2010 Targets
      STEP 1 (2005-7)             STEP 2 (2008-10)                New FY 2010 Targets

                                  Transition period
    Strategic investment
                                  for “high growth”               Consolidated sales
                                  High single-/ double-digit
                                       sales growth               of JPY 450 billion
                                                JPY 450 billion
                  【KSF* #2】                    (FY 2010 target)
                                                                  Operating profit of
                  Accelerated
                  strategic                                        JPY 100 billion
                  investment
                                     【KSF* #1】
JPY 327 billion
                                     Earlier launch of            • Top-class presence
                                     major products,
  (FY 2005)
                                     maximization of              • Highest growth
                                     product values
  Low single-digit sales growth                                   • WIN-WIN with Roche
 CAGR**in sales: (original) 4.2%           (new) 6.6 %
 * KSF=Key Success Factors             ** CAGR=Compound Annual Growth Rate
Position of FY 2006
 Leap toward the new FY 2010 targets
    Achieve filing of 8 projects and accelerate development of major
    projects
     • Filing of 8 projects
     • Approval of FEMARA (Jan), COPEGUS (2nd half of 2006)
     • Rapid development / Enhancement of in-licensing activities for Roche
       projects

    Transformation toward maximization of values for major projects
     • Enhancement of strategic marketing functions
     • Rapid strengthening of domestic sales forces
     • Acceleration of upgrading safety management system
Accelerated Filing Schedule
    Concentrated filings of 8 projects in 2006
                      INVIRASE         added
                           HIV
                       XELODA
                         Adj.CC
                      HERCEPTIN
                         Adj.BC                                  2 years earlier
                       AVASTIN
                          CRC
                                               1 year earlier
                       TARCEVA                                             GM-611
                         NSCLC                                            DG/Overseas
                       EPOGIN                         AVASTIN               ED-71          CERA
                           HD          added               NSCLC          Osteoporosis    Oncology
COPEGUS               OXAROL Lotion                   AVASTIN             BONVIVA        AVASTIN
Chronic hepatitis C      Psoriasis                          BC            Osteoporosis     Adj.CC
 EPOGIN               ACTEMRA         ACTEMRA          XELODA               CERA         HERCEPTIN
   Oncology             RA, sJIA      RA/Overseas          CRC            Renal anemia      GC

Filed (-2005)            2006           2007               2008                 2009-2011
              New molecular              Additional                       In-licensed
              entity                     indication etc.                  from Roche
Enhancement of Strategic Marketing Functions
   Earlier launch of major projects, maximization of
   products values
         July 2005: Built Strategic Marketing functions
                                  Lifecycle management
                                          strategy
                                                                       Earlier launch
                                                                       Maximization of
      Drug                           Late stage                        product values
                        PoC *                          Sales
      discovery                     development,
                                       filing                          Leading position
                                                                       in all present
                                                                       therapeutic areas
                   Therapeutic area strategy


* PoC=Proof of Concept (Verifies that the development concept shows efficacy in humans)
     Strengthening of Domestic Sales Force
      Establishment of robust franchises and realization
      of accelerated growth by oncology, renal and
      general MRs
                                                                  1,800 MRs ± α
                                             Approx.
                                            1,600 MRs

      1,400 MRs                                              ACTEMRA
                                                        PEGASYS・COPEGUS
                                                              AVASTIN
                             General MR                     HERCEPTIN
                                              900 MRs        TARCEVA
                 Oct 2004: Oncology MR                        XELODA
                                              400 MRs         FEMARA
                                                         EPOGIN (oncology)
                      July 2004: Renal MR                  EPOGIN, CERA
                                              300 MRs


End of;   2002                    2005        2006                    2010
Realization of High Growth with Innovative
New Drugs
                                 Global market
                              Access to the global market,
                                 either independently
                                  or in collaboration
            Chugai




                      Roche
Rich pipeline
                       Genentech
Domestic Market
Contacts: Corporate Communications


Investor Relations Group
Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp
Mac Uchida, Kae Maeda, Tomoko Ishida, Yusuke Tokita




                                                      12

								
To top